GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » EBIT

FGEN (FibroGen) EBIT : $-104.1 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is FibroGen EBIT?

FibroGen's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-13.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-104.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. FibroGen's annualized ROC % for the quarter that ended in Sep. 2024 was 8.22%. FibroGen's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -126.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. FibroGen's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 605.40%.


FibroGen EBIT Historical Data

The historical data trend for FibroGen's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen EBIT Chart

FibroGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -73.77 -186.33 -288.53 -293.43 -271.34

FibroGen Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -59.19 -51.70 -28.49 -10.92 -12.98

Competitive Comparison of FibroGen's EBIT

For the Biotechnology subindustry, FibroGen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where FibroGen's EV-to-EBIT falls into.



FibroGen EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-104.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FibroGen  (NAS:FGEN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

FibroGen's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=7.104 * ( 1 - -0.07% )/( (113.592 + 59.334)/ 2 )
=7.1089728/86.463
=8.22 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=293.203 - 118.741 - ( 140.714 - max(0, 148.589 - 209.459+140.714))
=113.592

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=264.421 - 151.088 - ( 131.003 - max(0, 190.53 - 244.529+131.003))
=59.334

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

FibroGen's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-51.904/( ( (72.129 + max(-92.813, 0)) + (9.696 + max(-125.457, 0)) )/ 2 )
=-51.904/( ( 72.129 + 9.696 )/ 2 )
=-51.904/40.9125
=-126.87 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.412 + 25.397 + 8.436) - (118.741 + 9.546 + 4.771)
=-92.813

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(29.03 + 23.937 + 6.255) - (151.088 + 28.858 + 4.733)
=-125.457

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

FibroGen's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-104.087/-17.193
=605.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FibroGen EBIT Related Terms

Thank you for viewing the detailed overview of FibroGen's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen Business Description

Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Executives
Thane Wettig officer: Chief Commercial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno director, officer: Chief Executive Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Christine Chung officer: SVP, China Operations C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck director C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner officer: Incoming Chief Medical Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham officer: Chief Financial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr director P O BOX 587, WARSAW IN 46581-0587
Pat Controneo officer: VP, Finance and CFO C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi director C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158